Document Detail

No role for cerebrospinal fluid myelin basic protein levels in patients treated for childhood acute lymphoblastic leukemia.
MedLine Citation:
PMID:  19648787     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Central nervous system prophylaxis of childhood acute lymphoblastic leukemia has dropped rates of relapses but has been associated with neurotoxicity and imaging abnormalities. Predictors of neurotoxicity are lacking, because of inconsistency between clinical symptoms and imaging. Some have suggested that cerebrospinal fluid myelin basic protein (MBP) levels to be of potential interest. A retrospective analysis of MBP levels in correlation with clinical and radiologic data is presented.
MATERIALS AND METHODS: MBP levels obtained at the time of intrathecals, charts, and neuroradiology reports were retrospectively analyzed. Academic achievement data were obtained from phone contacts with patients and families.
RESULTS: We retrieved 1248 dosages of MBP in 83 patients, 381 neurologic examinations in 34 patients and 69 neuroradiologic investigations in 27 patients. Fifty-two patients had abnormal MBP levels. Radiologic anomalies were present in 47% of those investigated, 14% of them having school difficulties. Proportions of patients with school difficulties in the groups with abnormal MBP levels but no radiologic anomalies or with no radiologic investigations were 0% and 3%, respectively, which was lower than in the group of patients with normal MBP levels (100%, 22%, and 5%, respectively).
DISCUSSION: Notwithstanding the retrospective character of our study, we conclude that there is limited usefulness of systematic dosage of MBP as indicator of treatment-induced neurotoxicity in acute lymphoblastic leukemia patients.
Manuel Diezi; Emma Garcia; Nicolas von der Weid; Maja Beck-Popovic
Related Documents :
7967757 - Efficacy of fluorescence in situ hybridization for detecting pml/rara gene fusion in tr...
13426797 - The carcinolytic effect of actinomycin c; a report of clinical studies.
10037027 - Abnormal patterns of immunoglobulin heavy chain gene dna fingerprinting during chronic ...
11934387 - Cytogenetic analysis in 139 tunisian patients with de novo acute myeloid leukemia.
7843847 - Characteristics of patients who choose between two types of group psychotherapy.
11924357 - Exploring the use of an alginate dressing for diabetic foot ulcers.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  31     ISSN:  1536-3678     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-08-03     Completed Date:  2009-09-04     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  393-7     Citation Subset:  IM    
Hematology-Oncology Unit, Department of Pediatrics, University Hospital, Lausanne, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  adverse effects*
Brain / pathology
Central Nervous System Neoplasms / prevention & control
Child, Preschool
Cognition Disorders / cerebrospinal fluid*,  etiology
Combined Modality Therapy / adverse effects
Cranial Irradiation
Infant, Newborn
Injections, Spinal
Myelin Basic Proteins / cerebrospinal fluid*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid*,  pathology,  therapy*
Reg. No./Substance:
0/Myelin Basic Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for hig...
Next Document:  Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Chi...